
|Articles|April 20, 2016
Metric Applied in Alternative iCardiac Safety Assessment Method
Advertisement
iCardiac Technologies announced the implementation of its quality metric--Method Bias Sensitivity (MBS)--into its Phase I QT assessment services. The metric compares the automated measurements from a timepoint to the measurements/values derived by that core lab’s methodology that was used for that particular study. Other metrics are under discussion by the Cardiac Safety Research Consortium members, however, iCardiac is implementing its metric after the ICH E14
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Quantifying the Net Financial Value of Deploying Risk-Based Quality Management
2
ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics
3
ACT Brief: Enterprise Risk Management, Execution Architecture for AI, and Rare Pediatric Regulatory Support
4
PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety
5




